Pumosetrag Hydrochloride, 羟色胺 3（5-HT3）受体部分激动剂

小分子

盐酸普莫司曲

Pumosetrag Hydrochloride

P655825-1ml

1ml

10mM in DMSO

干燥,-80℃储存

超低温冰袋运输

Pumosetrag Hydrochloride (MKC-733; DDP-733) is an orally available 5-HT3 partial agonist developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. In Vivo Pumosetrag displays both regional and species specificities. Pumosetrag has a lower efficacy than 5-HT in the rat jejunum, ileum and distal colon; however, it has similar efficacy and potency to 5-HT in the rat proximal colon. The activity profile of Pumosetrag is different in the guinea pig intestine where it exhibits greater potency and efficacy than 5-HT in all regions. Pumosetrag shows little to no response in the regions of the mouse intestine. Responses to Pumosetrag in the rat and guinea pig tissues are inhibited by ondansetron, confirming its action on 5-HT(3) receptors . Pumosetrag delays liquid gastric emptying in association with relaxation of the proximal stomach, stimulates fasting antroduodenal migrating motor complex activity and accelerates small intestinal transit. MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:5-HT 3 Receptor

Pumosetrag Hydrochloride（MKC-733；DDP-733）是一种口服 5-HT3 部分激动剂，用于治疗肠易激综合征和胃食管反流病。

194093-42-0(DMSO)

C15H18ClN3O2S

339.84 g/mol

C1CN2CCC1C(C2)NC(=O)C3=CNC4=C(C3=O)SC=C4.Cl

部分激动剂

羟色胺 3（5-HT3）受体部分激动剂